Status:
COMPLETED
Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Hospira, now a wholly owned subsidiary of Pfizer
Conditions:
Liver Transplantation
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
To test the effect of low-dose dexmedetomidine for lowering the incidence of postoperative delirium in liver transplant patients in the ICU. Single center prospective randomized placebo controlled cl...
Eligibility Criteria
Inclusion
- Adult patients (18years old or older) undergoing living-donor or deceased-donor liver transplantation
Exclusion
- Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2018
Estimated Enrollment :
217 Patients enrolled
Trial Details
Trial ID
NCT02245256
Start Date
September 1 2014
End Date
February 1 2018
Last Update
September 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, Agree, South Korea, 110-744